These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1746074)

  • 21. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
    Dearnaley DP; Norman AR; Shahidi M
    J Urol; 1999 Jul; 162(1):170. PubMed ID: 10379777
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmaceutical aspects. Nasal and depot formulations of leuprolide.
    Shimamoto T
    J Androl; 1987; 8(1):S14-6. PubMed ID: 3104262
    [No Abstract]   [Full Text] [Related]  

  • 24. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Pollack A; Horwitz EM
    Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
    [No Abstract]   [Full Text] [Related]  

  • 27. [Novel intermittent GnRHa therapy for patients with endometriosis].
    Tanaka T; Umesaki N
    Nihon Rinsho; 2001 Jan; 59 Suppl 1():124-8. PubMed ID: 11235149
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enatone-Gyn monthly depot): a multicenter study].
    Schindler AE; Bühler K; Gerhard I; Wiedemann R; Kimmig R; Schüssler B; Kranzfelder D; Mall-Häfeli M; Meinen K; Mancarella D
    Zentralbl Gynakol; 1994; 116(12):679-86. PubMed ID: 7846980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status].
    Stege R; Carlström K; Hedlund PO; Pousette A; von Schoultz B; Henriksson P
    Urologe A; 1995 Sep; 34(5):398-403. PubMed ID: 7483157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Primary endocrine therapy as pre- and perimenopausal metastatic breast carcinoma with leuprorelin acetate depot. German Leuprorelin Study Group].
    Untch M
    Zentralbl Gynakol; 1998; 120(6):284-92. PubMed ID: 9659699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
    DeAntoni E; Crawford ED
    Urologe A; 1995 Sep; 34(5):382-8. PubMed ID: 7483154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new injectable liquid crystal system for one month delivery of leuprolide.
    Ki MH; Lim JL; Ko JY; Park SH; Kim JE; Cho HJ; Park ES; Kim DD
    J Control Release; 2014 Jul; 185():62-70. PubMed ID: 24794897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers.
    Redding TW; Schally AV
    Prog Clin Biol Res; 1988; 262():217-40. PubMed ID: 2897695
    [No Abstract]   [Full Text] [Related]  

  • 37. Obesity and treatment of prostate cancer: what is the right dose of Lupron Depot?
    Agarwal N; Fletcher D; Ward J
    Clin Cancer Res; 2007 Jul; 13(13):4027. PubMed ID: 17606739
    [No Abstract]   [Full Text] [Related]  

  • 38. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
    J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leuprorelin acetate granulomas: case reports and review of the literature.
    Yasukawa K; Sawamura D; Sugawara H; Kato N
    Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
    Meinhardt W; Horenblas S
    J Urol; 1999 Jul; 162(1):170-1. PubMed ID: 10379778
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.